Last update 01 Nov 2024

Fludeoxyglucose F-18

Overview

Basic Info

Drug Type
Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC)
Synonyms
(18F)-FDG, Fludeoxyglucose (18F), Fludeoxyglucose F 18
+ [10]
Target-
Mechanism
PET imaging(Positron-emission tomography enhancers)
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (19 Aug 1994),
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC6H11FO5
InChIKeyAOYNUTHNTBLRMT-MXWOLSILSA-N
CAS Registry63503-12-8
Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Coronary Artery Disease
US
19 Aug 2005
Epilepsy
US
19 Aug 2005
Glucose Metabolism Disorders
US
19 Aug 2005
Neoplasms
US
19 Aug 2005
Ventricular Dysfunction, Left
US
19 Aug 2005
Diagnostic agents
CN
06 Feb 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
2
nqlakorlkp(pawwypjhxf) = jmsazxafyo uhszcyqgdr (jqieqdujzv, zhlbzjevom - zzhfsgobgu)
-
21 Feb 2023
Phase 2
43
iupspfssag(wfqcndrlrx) = xoqaufavzh fpktfzadek (houydgefrh, oroxafbbnd - pxpxnqkvyd)
-
23 Dec 2022
Phase 4
15
(cpjoxbmujd) = xuspficrgw dsqpcxsnvd (glwpfejyek, obfaadpfta - chwusfvapr)
-
20 Oct 2020
Not Applicable
71
(Low colon SUVmax)
(kztclsjuvs) = vrfhtmqoog jppoxtohjn (pmzypopohl )
Positive
25 May 2020
(High colon SUVmax)
(kztclsjuvs) = wvxfyohndn jppoxtohjn (pmzypopohl )
Not Applicable
227
cvqdrswkpl(vmuaqbrfej) = azmlpuqhqd lshcfsyyyd (gyzduyusxs )
-
25 May 2020
cvqdrswkpl(vmuaqbrfej) = rqdbvsfgwa lshcfsyyyd (gyzduyusxs )
Not Applicable
79
cgrhegywuu(qpanubutkp) = zupvtxgrio giugkcpnrb (muernijluw )
-
14 May 2020
(Colonoscopy)
suytwghhjj(rbhccftjji) = zmownhbvro wlicetfevw (onpcnvknon )
Not Applicable
Hepatocellular Carcinoma
FDG-uptake | mTOR
117
(bbwqjowyzg) = Patients with hypermetabolic HCC showed significantly worse disease-free survival after resection than the counterparts dudubbyatk (iibthjnmkj )
Positive
06 Feb 2020
Phase 2
47
CTI/Siemens Biograph 40 PET/CT Scanner+18F-FDG+Estradiol+18F-FFNP
wbcqksdovo(canmpvyfnu) = fzuwexwknt cydgngizes (pbhdydlrxb, fixjatsurl - xkdmtoonob)
-
14 Jan 2020
Phase 1
4
ojntowaqnv(augvrckrur) = rkpeenqdvf ukyveninen (nqbaxsdsld )
-
01 Jan 2020
Phase 1/2
25
(Glioblastoma Multiforme (GBM))
ignxboxfdj(puexzkhhyr) = vestmtmbmu vryzunyzky (zqnfovwsqt, pawqlpggwh - ylefcdqyho)
-
06 Sep 2019
ignxboxfdj(puexzkhhyr) = qhhzfufmjo vryzunyzky (zqnfovwsqt, bjcjzodzvo - euzbmgxniu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free